Anonymous
Guest
Anonymous
Guest
http://www.minyanville.com/sectors/...-advisory-committee-r2526d/5/22/2012/id/41183
In a harsh report on the company’s drug, Food and Drug Administration staff reviewers said Tuesday that Pfizer is trying to win approval for a treatment that lacks an acceptable study showing the product works.
“I recommend a complete response action, based on inadequate evidence of effectiveness,” says FDA reviewer Devanand Jillapalli in a document prepared for Thursday’s advisory panel. Complete response is FDA jargon for a rejection.
In a harsh report on the company’s drug, Food and Drug Administration staff reviewers said Tuesday that Pfizer is trying to win approval for a treatment that lacks an acceptable study showing the product works.
“I recommend a complete response action, based on inadequate evidence of effectiveness,” says FDA reviewer Devanand Jillapalli in a document prepared for Thursday’s advisory panel. Complete response is FDA jargon for a rejection.